BSE: ASTONEALAB · Healthcare · Pharmaceuticals · Market cap ₹373 Cr
· Prev close ₹348.10 · Volume 1.00 K · 52W ₹118–355
Company profile: not in our data yet
Net margin 3.1% (FY26)
Median of the other 5: 11.6%
Generated Return on capital is 13.8%, 3rd of 6 listed peers; Aptus Pharma is first at 24.2%.
Profit, last 4 quarters vs the 4 before: not in our data yet
Generated In FY26 revenue was +51.3% and net profit −15.6% on FY25.
2.2× the peers' median
Peers' median 36.7×
Generated At ₹355.00 the share is priced at 79.1× its earnings per share of ₹4.49 for the year to Mar 2026. The P/E at the FY26 year-end was 34.1×; the other 3 listed peers have a median of 36.7×.
Of profit came in as cash, last 5 fiscal years: not in our data yet
100%: all profit arrived as cash
Generated Operating cash was negative in FY26 and positive in the other one year; FY26 used ₹14 cr. Total debt was ₹21 cr at the end of FY26, against a net worth of ₹57 cr.
Held by domestic funds: not in our data yet
In 1 month: not in our data yet
Generated The 52-week range runs from ₹118 to ₹355; the 12 Nov close of ₹355.00 sits 100% of the way up. Over 1 year it is up 154.9%, and the close is above its 20 and 50-day averages of ₹228 and ₹187.
An earnings call transcript: not in our data yet
Scored statements from the earnings calls: none yet.
An earnings call transcript: not in our data yet